HIV / AIDS

Emergency departments (EDs) are an important entry point into the health care system and have been identified as a location with opportunity for increased HIV diagnosis and management.

The antiretroviral, lenacapavir (Sunlenca 463.5 mg/1.5 mL injection), had reported resistance in only a minority of study participants according to the latest findings released at a conference.

This action paves the way for this long-acting injectable to be used in several countries on the European continent.

Unique challenges can affect the success of the shift from pediatric to adult care settings.

The phase 1/2 trial evaluating EBT-101 dosed its first patient in September 2022.

The update refreshes the organization's 2022 guidance on HIV, viral hepatitis, and STI prevention, diagnosis, treatment, and care for key populations, focusing on people in prisons and other closed settings.

The twice-yearly injectable shown to be beneficial in conjunction with an optimized background regimen.

A new study shows the use of statin therapy in a primary prevention cohort of patients with HIV on antiretroviral therapy was associated with a 35% reduction in risk of cardiovascular events. The data is being reported at the International AIDS Society Conference.

New study demonstrates benefit of adhering to treatment regimen and also calls for simplifying viral testing in other parts of the world where updated panels technology may not be available.

A congressional subcommittee aims at reducing HIV-related budget items by over half a billion dollars.

New data from AIDSVu show significant disparities in the usage of HIV pre-exposure prophylaxis (PrEP). Black and Hispanic/Latinx Americans are underrepresented among PrEP users, despite accounting for a significant portion of new HIV diagnoses.

HIV testing is for everyone, explains Dr. Uri Belkind, regardless of sexual orientation, race, or gender.

As this annual day of recognition gets underway, free testing can be found throughout the United States.

This new antiretroviral with a unique mechanism of action may be lifesaving for those with treatment-resistant HIV infection.

Among mpox patients treated with tecovirimat, there was no difference in treatment outcomes between those living with HIV and those without HIV.

By addressing ART-related medication errors and increasing linkage to care, antiretroviral stewardship programs can improve management of inpatients with HIV.

The 340B program has had a great impact on access to HIV treatment and prevention services in the US.

When taken within 3 days, doxycycline given post-exposure (doxy-PEP) decreased the incidence rates of syphilis, gonorrhea, and chlamydia significantly.

ViiV Healthcare is working with 3 companies to manufacture generic versions of cabotegravir long-acting (LA).

The virus can maintain a reservoir in these white blood cells even in those who have been virally suppressed for years.

This week's hottest topics included the risks of proton pump inhibitors, rare tickborne disease, HIV vaccination, COVID-19 immunity from a common cold, and hydrocortisone for pneumonia.

Using a pregnant rabbit model, investigators found a robust antigen-specific antibody response in pregnant rabbits against HIV and Zika virus.

The patient, referred to as the “New York patient,” was treated with stem cells from cord blood, and has remained HIV-free in her blood since her transplant in 2017.

The Wistar Institute’s Amelia Escolano, PhD, is developing a novel approach using sequential immunization to capture protection against multiple strains.

The federal agency has taken a vital role in support and implementation of the ongoing PEPFAR initiative.

“HIV reservoir dynamics are driven by local inflammation and gut dysbiosis,” the investigators concluded.

Gut microbial abundance was observed to be independent of age and influenced COVID-19 spike IgG levels.

Primary care physicians and advanced practice providers are responsible for the majority of people seeking medical care in the United States, yet there is a gap in discussing sexual health for those who are at risk of HIV or other sexually-transmitted diseases.

“The combination of the 2 drugs was shown in this trial to be noninferior to the standard 3-drug regimen,” said Jean Michel Molina, MD, PhD, lead investigator of Merck’s islatravir/doravirine study.